Literature DB >> 33913588

No relationship was observed between Kawasaki disease and COVID-19 in Japan.

Yosikazu Nakamura1.   

Abstract

Entities:  

Keywords:  COVID-19; Japan; mucocutaneous lymph node syndrome

Mesh:

Year:  2021        PMID: 33913588      PMCID: PMC8242650          DOI: 10.1111/ped.14515

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.617


× No keyword cloud information.
During the time of the COVID‐19 pandemic, there have been reports on the relationship between Kawasaki disease (KD) and SARS‐Cov‐2 from the United States, Europe, and other parts of the world. , However, there have been no such reports from Japan, until now. Japan has the largest number of KD patients in the world. Besides a nationwide survey of KD, Japan also has a national surveillance system of the disease. , Under this system, 199 participating hospitals promptly register all patients who have been diagnosed with KD by a pediatrician. On July 13 2020, all the participating hospitals were asked to report the number of KD patients with a polymerase chain reaction (PCR) test and the number of positive PCR cases among them. Of the 199 hospitals, 50 responded by July 21. A total of 496 KD patients were registered by the 50 hospitals between January 1 and July 21 2020. Of the 496 patients, PCR was conducted for 81 patients, including six patients with both a PCR and an antigen test. In addition, an antigen test was conducted for 12 patients and a loop‐mediated isothermal amplification test was administered to another five patients. None of the 98 patients tested presented a positive result for SARS‐Cov‐2. For the other 412 KD patients, the pediatricians treating them did not consider it necessary to conduct a test for the virus because of the patients’ symptoms, laboratory data, and other relevant information. In other words, patients with KD who did not present the COVID‐19 symptoms were not tested with PCR; however, this may be a limitation of this observation. Finally, the situation regarding Covid‐19 infection in Japan, according to the Ministry of Health, Labour and Welfare, as of August 19 2020 is presented. In conclusion, according to our observation, no KD patients showed a relationship with COVID‐19 in Japan. Among 57 140 patients with COVID‐19, there were 1,144 (2.0%) patients who were younger than 10 years, with no severe nor fatal cases (https://www.mhlw.go.jp/content/10906000/000661165.pdf). According to our observation, no KD patients showed a relationship with COVID‐19 in Japan.

Funding

This study received funding from the Japan Kawasaki Disease Research Center, a non‐profit organization.

Disclosure

The author declares no conflict of interest.
  4 in total

1.  Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: The Nationwide Survey in Japan, 2017-2018.

Authors:  Ryusuke Ae; Nobuko Makino; Koki Kosami; Masanari Kuwabara; Yuri Matsubara; Yosikazu Nakamura
Journal:  J Pediatr       Date:  2020-05-23       Impact factor: 4.406

2.  COVID-19 and Kawasaki Disease: Novel Virus and Novel Case.

Authors:  Veena G Jones; Marcos Mills; Dominique Suarez; Catherine A Hogan; Debra Yeh; J Bradley Segal; Elizabeth L Nguyen; Gabrielle R Barsh; Shiraz Maskatia; Roshni Mathew
Journal:  Hosp Pediatr       Date:  2020-04-07

3.  Characteristics and validity of a web-based Kawasaki disease surveillance system in Japan.

Authors:  Yosikazu Nakamura; Mayumi Yashiro; Ryusuke Ae; Izumi Chihara; Atsuko Sadakane; Yasuko Aoyama; Kazuhiko Kotani; Ritei Uehara; Shohei Harada
Journal:  J Epidemiol       Date:  2010-08-28       Impact factor: 3.211

4.  Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic.

Authors:  Ashraf S Harahsheh; Nagib Dahdah; Jane W Newburger; Michael A Portman; Maryam Piram; Robert Tulloh; Brian W McCrindle; Sarah D de Ferranti; Rolando Cimaz; Dongngan T Truong; Jane C Burns
Journal:  J Pediatr       Date:  2020-05-03       Impact factor: 4.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.